
CrisBio® applications in OneHealth
Most advanced projects

INFLUENZA
H1N1; H7N9; H5N1

CoV-19

HPV

Anti Human rotavirus VP6
VACCINES
Algenex has completed a proof of concept study in avian influenza, a zoonotic disease that has the potential to turn into a global pandemic. In this study, Algenex demonstrated its ability to develop a fully functional and safe vaccine in only four months.
Using CrisBio®, Algenex is ideally positioned to produce and supply large quantities of proteins to pharmaceutical companies developing and manufacturing vaccines quickly and at competitive prices. This would enable widespread immunization, in particular in countries with weak economies and less advanced public health systems.
DIAGNOSTICS
Algenex has licensed its CrisBio® technology to Biokit (Werfen Group), who is commercializing two diagnostic kits for human applications based on Algenex’ technologies.